Continue to Site

Drug Discovery and Development

Nubeqa offers promise to prostate cancer patients

By |

DUBEQ non-metastatic castration resistant prostate cancer Bayer Orion Corp.FDA indicates Nubeqa (darolutamide) to treat patients with non-metastatic castration-resistant prostate cancer.

Bayer and Orion Corp. jointly developed the drug, which FDA approved in 2019. The approval came after FDA reviewed results from the Phase 3 ARAMIS study, which tested Nubeqa with androgen deprivation therapy (ADT) in patients with prostate cancer.

The drug has continued to show promise in the Phase 3 ARAMIS trial in supporting metastasis-free survival.

Bayer is currently running a Phase 2 trial of the drug in breast cancer patients.

Filed Under: Oncology
Tagged With: , , , , ,
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Tell Us What You Think!

Related Articles Read More >

Search Drug Discovery & Development